AMACR and prostate carcinoma: Nevertheless, the combined mRNA and protein data from the cross-sections could suggest that qRT-PCR assays are more sensitive than immunohistochemistry to reveal potential carcinoma lesions, because in accordance with our results for carcinoma samples in immunohistochemical analysis, it has been reported that some small foci of prostate cancers can be negative for AMACR staining [34].